Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)

Sponsor
Washington University School of Medicine (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05049863
Collaborator
(none)
30
1
3
22
1.4

Study Details

Study Description

Brief Summary

The hypothesis is that the addition of mycophenolate mofetil (MMF) and allopurinol to chemotherapy in patients with relapsed small cell lung cancer (SCLC) will be safely tolerated and improve outcomes, as measured by response rate and progression-free survival in patients compared to other single agent chemotherapy drugs used in historical controls.

Condition or Disease Intervention/Treatment Phase
Phase 1/Phase 2

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Non-Randomized
Intervention Model:
Sequential Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evaluating the Safety and Efficacy of Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
Anticipated Study Start Date :
Sep 30, 2022
Anticipated Primary Completion Date :
Jan 31, 2024
Anticipated Study Completion Date :
Jul 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Phase I Dose Level 0: MMF + Irinotecan + Allopurinol

-Mycophenolate mofetil (MMF) will be administered at a dose of 1 g TID (3 g/day) on a daily basis (Days 1 through 21). Allopurinol will be administered at dose of 300 mg/day on a daily basis (Days 1 through 21). Irinotecan will be given at the assigned dose level on Days 1 and 8. Cycles are 21 days.

Drug: Mycophenolate Mofetil
Mycophenolate mofetil is commercially available.
Other Names:
  • MMF
  • Cellcept
  • Drug: Allopurinol
    Allopurinol is commercially available.
    Other Names:
  • Zyloprim
  • Aloprim
  • Drug: Irinotecan
    Irinotecan is commercially available.
    Other Names:
  • Onivyde
  • Camptosar
  • Experimental: Phase I Dose Level 1: MMF + Irinotecan + Allopurinol

    -Mycophenolate mofetil (MMF) will be administered at a dose of 1 g TID (3 g/day) on a daily basis (Days 1 through 21). Allopurinol will be administered at dose of 300 mg/day on a daily basis (Days 1 through 21). Irinotecan will be given at the assigned dose level on Days 1 and 8. Cycles are 21 days.

    Drug: Mycophenolate Mofetil
    Mycophenolate mofetil is commercially available.
    Other Names:
  • MMF
  • Cellcept
  • Drug: Allopurinol
    Allopurinol is commercially available.
    Other Names:
  • Zyloprim
  • Aloprim
  • Drug: Irinotecan
    Irinotecan is commercially available.
    Other Names:
  • Onivyde
  • Camptosar
  • Experimental: Phase II: MMF + Irinotecan + Allopurinol

    -Mycophenolate mofetil (MMF) will be administered at a dose of 1 g TID (3 g/day) on a daily basis (Days 1 through 21). Allopurinol will be administered at dose of 300 mg/day on a daily basis (Days 1 through 21). Irinotecan will be given at the assigned dose level on Days 1 and 8. Cycles are 21 days.

    Drug: Mycophenolate Mofetil
    Mycophenolate mofetil is commercially available.
    Other Names:
  • MMF
  • Cellcept
  • Drug: Allopurinol
    Allopurinol is commercially available.
    Other Names:
  • Zyloprim
  • Aloprim
  • Drug: Irinotecan
    Irinotecan is commercially available.
    Other Names:
  • Onivyde
  • Camptosar
  • Outcome Measures

    Primary Outcome Measures

    1. Number of study treatment related adverse events as measured by NCI-CTCAE v 5.0 (Phase I only) [Through 30 days after completion of treatment (estimated to be 5 months)]

    2. Overall response rate (ORR) (Phase II only) [Through completion of treatment (estimated to be 4 months)]

      ORR is defined as the proportion of patients achieving a complete response (CR) or partial response (PR) according to RECIST 1.1 Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Disappearance of all non-target lesions and normalization of tumor marker level. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

    3. Maximum tolerated dose (MTD)/Recommended phase II dose (RP2D) (Phase I only) [Completion of cycle 1 (each cycle is 21 days) of all enrolled Phase I participants (estimated to be 10 months)]

      -The maximum tolerated dose (MTD)/recommended phase II dose (RP2D) is defined as the dose level immediately below the dose level at which 2 patients of a cohort (of 2 to 6 patients) experience dose-limiting toxicity during the first cycle.

    4. Number of discontinuations due to treatment related adverse events (Phase I only) [Through completion of treatment (estimated to be 4 months)]

    Secondary Outcome Measures

    1. Progression-free survival (PFS) (Phase II only) [Through 6 months after completion of treatment (estimated to be 10 months)]

      -Progression-free survival (PFS), defined as the duration of time from the start date of study treatment to the date of earliest progression or death, whichever occurs first. Patients who neither progress nor die by the data cutoff date will be censored at the last follow up date.

    2. Overall survival (OS) (Phase II only) [Through 6 months after completion of treatment (estimated to be 10 months)]

      -Overall survival (OS), defined as the duration of time from the start date of study treatment to death from any cause. Patients who are alive by the data cutoff date will be censored at the last follow up date.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Histologically or cytologically confirmed small cell lung cancer that has progressed on prior systemic therapy

    • Presence of measurable disease per RECIST 1.1 criteria

    • At least 18 years of age.

    • ECOG performance status ≤ 2

    • Normal bone marrow and organ function as defined below:

    • Absolute neutrophil count ≥ 1,500 K/mm3

    • Platelets ≥ 100,000 K/mm3

    • Hemoglobin ≥ 9.0 g/dL

    • Total bilirubin ≤ 1.5 x IULN

    • AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN (≤ 5 x IULN for patients with liver metastases)

    • Creatinine ≤ 1.5 x IULN OR measured or calculated creatinine clearance > 50 mL/min for patients with creatinine levels > 1.5 x IULN

    • Use of MMF during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations (especially external ear and other facial abnormalities including cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, kidney, and nervous system). For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry, for the duration of study participation, and for 6 weeks after stopping study treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and 90 days after last dose of study treatment. Women must not be breastfeeding.

    • Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

    Exclusion Criteria:
    • A history of other malignancy with the exception of: (a) malignancies for which the patient has no evidence of disease at time of screening, and (b) the diagnosis is unlikely to pose a competing mortality risk in the opinion of the treating provider, and (c) for which the patient does not actively require therapy.

    • Previous intolerance to irinotecan. Treatment with prior irinotecan is allowed as along as treatment was not discontinued for treatment related adverse events.

    • Unable to swallow pills or take study medications orally in accordance with administration schedule outlined

    • Currently receiving any other investigational agents.

    • Patients with untreated symptomatic brain metastases are excluded. Patients with clinically evident CNS hemorrhage are excluded. Patients with brain metastases treated with whole brain radiation therapy, radiosurgery, or surgery are eligible. Patients with asymptomatic brain metastases (measuring less than 10 mm) are allowed.

    • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to MMF, allopurinol or other agents used in the study.

    • Diarrheal illnesses such as inflammatory bowel disease that requires medical therapy.

    • History of active autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Bell's palsy, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis for which the patient requires active immunosuppressive therapy.

    • Pneumonitis, including organizing pneumonias related to previous treatment, for which patients require active treatment or supplemental oxygen support.

    • Active infections or those patients who are not candidates for immunosuppression with MMF.

    • Undergone major surgery within 28 days prior to Cycle 1 Day 1, or minor surgery/subcutaneous venous access device placement within 7 days prior to Cycle 1 Day 1, or has elective or planned major surgery to be performed during the course of the clinical trial.

    • Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis, cirrhosis at a level of Child-Pugh B or worse, cirrhosis (any degree) with a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis (defined as ascites from cirrhosis requiring diuretics or paracentesis), fatty liver, and inherited liver disease.

    • Active tuberculosis.

    • Severe infections within 2 weeks prior to Cycle 1 Day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.

    • Unresolved grade 2 or higher toxicities from previous treatment with the exception of fatigue, endocrine AEs that are being managed with hormone replacement, or alopecia.

    • Received oral or intravenous (IV) antibiotics within 2 weeks prior to Cycle 1 Day 1

    • Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to C1D1.

    • Active hepatitis B (chronic or acute) defined as having a positive hepatitis B surface antigen (HBsAg) test at screening. Note: Patients with past or resolved hepatitis B infection (defined as having a negative HBsAg test and a positive total hepatitis B core antibody (HBcAb) test are eligible.

    • Patients known to be HIV positive are ineligible.

    • SN-38 is metabolized by CYP3A4 enzymes, and therefore patients enrolling to this study should be prohibited from use of medications known to be strong inducers or inhibitors of CYP3A4. Strong CYP3A4 inducers should be discontinued for at least 2 weeks before starting irinotecan therapy. Strong CYP3A4 inhibitors should be discontinued at least 1 week before starting irinotecan therapy.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Washington University School of Medicine Saint Louis Missouri United States 63110

    Sponsors and Collaborators

    • Washington University School of Medicine

    Investigators

    • Principal Investigator: Siddhartha Devarakonda, MBBS, M.D., Washington University School of Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Washington University School of Medicine
    ClinicalTrials.gov Identifier:
    NCT05049863
    Other Study ID Numbers:
    • 21-x082
    First Posted:
    Sep 20, 2021
    Last Update Posted:
    May 18, 2022
    Last Verified:
    May 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 18, 2022